Associate Attending Physician, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York
Co-Investigator: Angelo Di Leo, MD, PhD, Head of Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Prato, Italy
There is much exciting data emerging about metabolic changes associated with breast cancer. Drs. Di Leo and Fornier are using metabolomics –the rapid, high throughput characterization of the small molecule metabolites found in an organism – to explore a model in which serum detectable metabolic profiles correlate with disease recurrence. Furthermore, they are evaluating whether the combination of metabolomics and the 21 gene recurrence score (OncotypeDx®) genomic test, might further improve prediction of disease recurrence, and thus refine prognostication in individuals with early stage breast cancer.
Drs. DiLeo and Fornier have already found promising results from the first part of this project and are now investigating firstly whether these results can be confirmed in a larger group of women, and secondly whether metabolomics can be effectively combined with another risk prediction test, Oncotype DX, which looks are tumor genetic changes. Results from these projects could help improve the ability to select which women with early breast cancer are at higher risk of disease recurrence and therefore would have the most benefit from the addition of chemotherapy after their breast cancer surgery.
Dr. Monica Fornier is an Assistant Member at the Breast Cancer Medicine Service of Memorial Sloan-Kettering Cancer Center, and specializes in the treatment of breast cancer. She is also an Assistant Professor at the Weill Medical College of Cornell University, New York Presbyterian Hospital
Dr. Fornier graduated summa cum laude at the University of Milan (Italy); she pursued her Oncology fellowship at the National Cancer Institute of Milan, under the mentorship of Dr. Gianni Bonadonna, and a second fellowship at Memorial Sloan Kettering Cancer Center in New York, under the mentorship of Dr. Larry Norton. She is currently a member of the Faculty at Memorial Sloan-Kettering Cancer Center, where she conducts clinical research in breast cancer. Dr. Fornier has been involved in the development and conduction of numerous clinical trials assessing novel drugs and drug scheduling strategies for the treatment of breast cancer, both in the adjuvant and metastatic setting.
Dr Fornier is an active member of various national and international scientific groups, including the American Society of Clinical Oncology and the European Society of Medical Oncology. Dr Fornier has numerous publications to her name and has presented data at international meetings.